# Convenience
Keywords: PLEGRIDY, Multiple Sclerosis, RRMS, Disease Modifying Therapy, Intramuscular, Subcutaneous, Patient Support, Adverse Events

> This page provides information about PLEGRIDY, a therapy for Relapsing-Remitting Multiple Sclerosis (RRMS), highlighting its convenience, dosing options, patient support resources, and adverse event reporting guidelines.

## Details
- [Convenience](#): PLEGRIDY offers fortnightly self-administration options (intramuscular or subcutaneous) with the lowest dosing frequency among MS platform therapies.
- [PLEGRIDY Options](#): Provides treatment choices with pre-filled syringes or pens for intramuscular or subcutaneous administration.
- [What support is available for your patients?](#): Details patient hubs and downloadable materials to aid healthcare professionals in supporting patients.
- [PLEGRIDY patient hubs](#): Offers links to dedicated hubs for intramuscular and subcutaneous PLEGRIDY resources.
- [Patient Support Downloads](#): Contains downloadable materials for healthcare professionals to discuss treatment options with patients.
- [References and abbreviations](#): Lists abbreviations and references related to PLEGRIDY and MS therapies.
- [Adverse Events Reporting](#): Provides guidelines for reporting adverse events in the UK and Ireland.